Mostrar el registro sencillo del ítem
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
dc.rights.license | open | en_US |
hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
dc.contributor.author | BROCHET, Bruno | |
hal.structure.identifier | Maastricht University Medical Centre [MUMC] | |
dc.contributor.author | HUPPERTS, Raymond | |
hal.structure.identifier | Royal Holloway [University of London] [RHUL] | |
dc.contributor.author | LANGDON, Dawn | |
hal.structure.identifier | Fondazione IRCCS Istituto Neurologico "Carlo Besta" | |
dc.contributor.author | SOLARI, Alessandra | |
hal.structure.identifier | Karolinska Institutet [Stockholm] | |
dc.contributor.author | PIEHL, Fredrik | |
hal.structure.identifier | University of Newcastle [Callaghan, Australia] [UoN] | |
dc.contributor.author | LECHNER-SCOTT, Jeannette | |
hal.structure.identifier | Vall d'Hebron University Hospital [Barcelona] | |
hal.structure.identifier | Centre d'Esclerosi Múltiple de Catalunya [CemCat] | |
dc.contributor.author | MONTALBAN, Xavier | |
hal.structure.identifier | Department of Neurology and Stroke, Medical University of Lodz | |
dc.contributor.author | SELMAJ, Krzysztof | |
hal.structure.identifier | First Faculty of Medicine Charles University | |
dc.contributor.author | VALIS, Martin | |
hal.structure.identifier | Medical University of Lublin | |
dc.contributor.author | REJDAK, Konrad | |
dc.contributor.author | HAVRDOVA, Eva K. | |
hal.structure.identifier | Università degli studi di Catania = University of Catania [Unict] | |
dc.contributor.author | PATTI, Francesco | |
hal.structure.identifier | Merck KGaA [Darmstadt, Germany] | |
dc.contributor.author | ALEXANDRI, Nektaria | |
hal.structure.identifier | Merck KGaA [Darmstadt, Germany] | |
dc.contributor.author | NOLTING, Axel | |
hal.structure.identifier | Merck KGaA [Darmstadt, Germany] | |
dc.contributor.author | KELLER, Birgit | |
dc.date.accessioned | 2023-01-09T13:51:26Z | |
dc.date.available | 2023-01-09T13:51:26Z | |
dc.date.issued | 2022-01 | |
dc.identifier.issn | 2211-0348 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/171622 | |
dc.description.abstractEn | Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) have been approved for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS). The ongoing CLARIFY-MS study (NCT03369665; EudraCT number: 2017-002632-17) aims to assess the effect of cladribine tablets 3.5 mg/kg on HRQoL of patients with highly active RMS. Objective To report on the design of the CLARIFY-MS study, baseline patient characteristics, and results of a pre-planned interim analysis focusing on treatment satisfaction, safety, and tolerability that includes all data reported till 6 months after start of treatment. Methods The CLARIFY-MS study is a 2-year, open-label, single-arm, prospective, multicenter, phase IV study. Eligible patients with highly active RMS were assigned to receive cladribine tablets 3.5 mg/kg over 2 years. Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM, v1.4; scale range from 0 to 100, higher values indicating higher satisfaction). Safety assessments, including occurrence of treatment-emergent adverse events (TEAEs; any adverse event reported after drug administration), serious adverse events (SAEs), and lymphocyte counts, were summarized descriptively. Results A total of 482 patients from 85 sites in Europe were treated with cladribine tablets. Mean patient age was 37.4 years, 338 (70.1%) were women, median EDSS was 2.5, and 345 (71.6%) were prior users of disease-modifying therapy (DMT). During the first 6 months after the start of treatment, and before reaching the full dose of cladribine tablets, mean TSQM global satisfaction score for the overall population was 70.4 (standard deviation, ± 18.48). The side effects score was 91.9 (± 17.68), convenience scored 86.6 (± 13.57), and effectiveness was 65.8 (± 21.14). A total of 275 patients (57.1%) reported at least one TEAE and 9 patients (1.9%) had a SAE. The majority of observed lymphopenia cases were of grade 1 or 2; 33 (6.8%) of the total study cohort had grade 3 lymphopenia, and no grade 4 lymphopenia was reported. Conclusion Patients reported high treatment satisfaction (TSQM) with cladribine tablets in this pre-planned interim analysis at 6 months. Few serious, and no unexpected, adverse events were reported, and there were no instances of grade 4 lymphopenia over the first 6 months. These preliminary data indicate good tolerability and convenience of administration of cladribine tablets in patients with highly active RMS. © 2021 The Author(s) | |
dc.language.iso | EN | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject.en | Cladribine tablets | |
dc.subject.en | Treatment satisfaction | |
dc.subject.en | Relapsing multiple sclerosis | |
dc.title.en | Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis | |
dc.title.alternative | Mult Scler Relat Disord | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1016/j.msard.2021.103385 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
dc.identifier.pubmed | 35158476 | en_US |
bordeaux.journal | Multiple Sclerosis and Related Disorders | en_US |
bordeaux.page | 103385 | en_US |
bordeaux.volume | 57 | en_US |
bordeaux.hal.laboratories | Neurocentre Magendie - U1215 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | Relations glie-neurone | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
bordeaux.identifier.funderID | Merck KGaA | en_US |
hal.identifier | hal-03930938 | |
hal.version | 1 | |
hal.date.transferred | 2023-01-09T13:51:36Z | |
hal.export | true | |
dc.rights.cc | CC BY | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Multiple%20Sclerosis%20and%20Related%20Disorders&rft.date=2022-01&rft.volume=57&rft.spage=103385&rft.epage=103385&rft.eissn=2211-0348&rft.issn=2211-0348&rft.au=BROCHET,%20Bruno&HUPPERTS,%20Raymond&LANGDON,%20Dawn&SOLARI,%20Alessandra&PIEHL,%20Fredrik&rft.genre=article |